Creatine and Motor Skill Acquisition

Sponsor
University of Regina (Other)
Overall Status
Recruiting
CT.gov ID
NCT05201651
Collaborator
(none)
36
1
2
6.6
5.4

Study Details

Study Description

Brief Summary

The investigators will conduct a double-blind, placebo-controlled, repeated measures study of the effects of oral creatine monohydrate supplementation on motor skill acquisition and neurophysiology in young healthy adults. After baseline testing, participants will be randomized to receive creatine supplementation or placebo for seven days. Participants will then complete three days of training on a motor skill task while consuming a maintenance dosage of creatine or placebo. TMS measures of neurophysiology will be assessed at baseline, and pre- and post-skill training on the first and third training days.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Creatine Monohydrate
  • Dietary Supplement: Maltodextrin Placebo
Early Phase 1

Detailed Description

Participants: Thirty-six young healthy adults between 18-39 years of age will participate in the study. Participants will follow an omnivore diet given differences in response to creatine supplementation among vegetarians.

Group allocation: Participants will be allocated to study groups (i.e., creatine, placebo) using blocked randomization that stratifies by sex (male, female).

Supplementation and diet: An individual blind to supplement and group allocation will prepare participant study kits. Each study kit will contain daily supplementation bags for the duration of the study, detailed instructions, and a compliance log. Creatine (Creapure® AlzChem Trostberg GmbH, Germany) and placebo (Globe Plus 10 DE Maltodextrin, Univar Canada) will be in powder form and be very similar in color, texture, and appearance. After baseline testing, participants will orally consume creatine or placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days. This 3-g/day dosage has been shown to maintain cellular creatine levels. Adherence with the supplementation protocol will be assessed by the compliance log. Possible adverse events to supplementation (i.e., minor gastrointestinal irritation) will be assessed using adverse event forms. Upon completion of the study, participants will be asked to guess whether creatine or placebo had been administered. Habitual dietary intake will be determined by 3-day food logs completed by participants prior to the study.

Motor skill task: Participants will perform an "intercept and release" task which uses a Microsoft Kinect sensor and open-source software to track 3-dimensional joint movement. Participants will be instructed to "save the world" through control of an on-screen cursor (i.e., spaceship) using movement of their dominant arm to intercept a moving object (an asteroid) as it emerges from the side of a computer screen. After interception of the object, participants will be required to accurately throw the object to hit a target (the sun). The task will progress through 10 stages of increasing difficulty (i.e., increasing object speed, decreasing target size) as skill performance improves. The stages of difficulty are designed to challenge participants, maintain engagement, and prevent plateaus in performance.

Participants will complete one block of 200 movements (i.e., 100 object interceptions, 100 object throws) at the easiest level of difficulty in the baseline testing session. After the initial 7-day creatine supplementation period, three training sessions will be completed on consecutive days. A training session will involve five blocks of 200 movements, for 1,000 skilled arm movements per session (~45 minutes), and a total of 3,000 training movements over the course of the study. A plot of object interception time (y-axis) by successful movement trial (x-axis) across the training period (i.e., days 1-3) will be generated for each participant and fit with an exponential curve. The curve fitting parameter that represents rate of skill acquisition will be extracted for each participant as the primary dependent variable.

Transcranial magnetic stimulation (TMS): Using neuronavigation software, TMS will be applied over the primary motor cortex to elicit motor evoked potentials (MEPs) in the extensor carpii radialis muscle of the dominant arm, a muscle involved in performance of the motor skill task. Using standard procedures, the investigators will collect a battery of TMS measures that provide indices of corticospinal excitability and gamma-aminobutyric acid and glutamate signaling at baseline, and pre- and post-skill training on the first and third days.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants assigned to receive creatine supplementation or placebo.Participants assigned to receive creatine supplementation or placebo.
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Double blind. Individual without other involvement in study has study codes and prepares and distributes study kits containing creatine and placebo (similar appearance).
Primary Purpose:
Basic Science
Official Title:
Effects of Creatine Supplementation on Motor Skill Acquisition and Related Neurophysiology
Actual Study Start Date :
Feb 10, 2022
Anticipated Primary Completion Date :
Aug 31, 2022
Anticipated Study Completion Date :
Aug 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Creatine

Participants will orally consume creatine (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.

Dietary Supplement: Creatine Monohydrate
Participants will orally consume creatine (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days. This 3-g/day dosage has been shown to maintain cellular creatine levels.

Placebo Comparator: Placebo

Participants will orally consume maltodextrin placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.

Dietary Supplement: Maltodextrin Placebo
Participants will orally consume maltodextrin placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.

Outcome Measures

Primary Outcome Measures

  1. Rate of change in movement time [3 days]

    Both groups will perform a skill acquisition task that involves moving the dominant upper limb to direct a cursor towards moving targets presented on a computer screen. The task will be practiced over a period of three days. The time required to reach each moving target will be measured (i.e., movement time) with faster times indicating improved performance. The rate of improvement on the task over the three days will be determined.

Secondary Outcome Measures

  1. Single pulse motor evoked potential amplitude [Days 1 and 3 of training]

    Amplitude of motor evoked potentials measured with electromyography and elicited by single-pulse transcranial magnetic stimulation. Provides a marker of corticospinal excitability.

  2. Short-interval intracortical inhibition motor evoked potential amplitude [Days 1 and 3 of training]

    Amplitude of motor evoked potentials measured with electromyography and elicited by transcranial magnetic stimulation using paired-pulse short interval intracortical inhibition paradigm.

  3. Intracortical facilitation motor evoked potential amplitude [Days 1 and 3 of training]

    Amplitude of motor evoked potentials measured with electromyography and elicited by transcranial magnetic stimulation using paired-pulse intracortical facilitation paradigm.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 39 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • omnivore diet
Exclusion Criteria:
  • pre-existing liver abnormalities

  • pre-existing kidney abnormalities

  • pre-existing neuromuscular abnormalities

  • contraindications to transcranial magnetic stimulation

  • consumption of dietary supplements containing creatine within 30 days prior to the start of the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Regina Regina Saskatchewan Canada S4S5N6

Sponsors and Collaborators

  • University of Regina

Investigators

  • Principal Investigator: Cameron S Mang, PhD, University of Regina

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Regina
ClinicalTrials.gov Identifier:
NCT05201651
Other Study ID Numbers:
  • 2021-139
First Posted:
Jan 21, 2022
Last Update Posted:
Feb 24, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Regina

Study Results

No Results Posted as of Feb 24, 2022